Senores Pharmaceuticals Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 26, 2026
- Posted by: Ankit Jaiswal
- Category: News
The Senores Pharmaceuticals share price target 2026 is Rs 1,500, implying approximately 20 percent upside from the current market price of Rs 1,270 (NSE: SENORES). With Q4 FY26 results released in 2026 and Generic Pharmaceuticals Export tailwinds in focus, the Rs 1,500 price objective is supported by the FY27 earnings recovery thesis.
Senores Pharmaceuticals (NSE: SENORES) is a Generic Pharmaceuticals Export company trading at Rs 1,270 with a market capitalisation of Rs 5,844 crore. Analysts have set the Senores Pharmaceuticals share price target at Rs 1,500 for 2026, based on FY27 earnings projections and sector re-rating potential. According to Ankit Jaiswal, Senior Research Analyst at Univest, the Rs 1,500 price objective reflects improving fundamentals in the Generic Pharmaceuticals Export space. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
Senores Pharmaceuticals Share Price Target 2026: Key Takeaways
- Senores Pharmaceuticals share price target 2026: Rs 1,500 (20% upside from CMP Rs 1,270)
- Bull case: Rs 1,850 | Bear case: Rs 1,000
- Ticker: SENORES | Sector: Generic Pharmaceuticals Export | MCap: Rs 5,844 crore
- 52W range: Rs 532 to Rs 1,360 | PE: 20x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
Senores Pharmaceuticals Company Overview
Senores Pharmaceuticals (NSE: SENORES) is a Ahmedabad-based generic pharmaceutical company manufacturing and exporting branded and unbranded generic formulations to regulated markets in the US, Europe, and Rest of World, listed in 2024. At CMP Rs 1,270 against a 52 week range of Rs 532 to Rs 1,360, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 5,844 crore with trailing PE of 20x. Compared to peers in pharma export like Alembic Pharmaceuticals and Neuland Laboratories, Senores Pharmaceuticals is positioned as a potential re-rating candidate toward the Rs 1,500 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | SENORES |
| Sector | Generic Pharmaceuticals Export |
| CMP (2026) | Rs 1,270 |
| 52 Week High | Rs 1,360 |
| 52 Week Low | Rs 532 |
| Market Cap | Rs 5,844 crore |
| Trailing PE | 20x |
| 12-Month Analyst Target | Rs 1,500 |
| Bull Case Target | Rs 1,850 |
| Bear Case Target | Rs 1,000 |
Why Is the Senores Pharmaceuticals Share Price Target Set at Rs 1,500 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Senores Pharmaceuticals share price target of Rs 1,500 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Ankit Jaiswal at Univest notes that Q4 FY26 results confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 1,270.
Structural Sector Tailwinds in Generic Pharmaceuticals Export
The Generic Pharmaceuticals Export sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Senores Pharmaceuticals’s position among peers in pharma export like Alembic Pharmaceuticals and Neuland Laboratories creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 1,850 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Senores Pharmaceuticals’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 1,500 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Senores Pharmaceuticals’s Generic Pharmaceuticals Export operations, improving the probability of achieving the Rs 1,500 price objective through FY27 earnings delivery.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 20x PE, Senores Pharmaceuticals is positioned as a beneficiary of institutional reallocation toward the Rs 1,850 bull case over the medium term.
Senores Pharmaceuticals Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Senores Pharmaceuticals Share Price Target
Near-term support for Senores Pharmaceuticals is anchored close to the 52 week low of Rs 532. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 1,270.
12-Month Senores Pharmaceuticals Share Price Target 2026
The 12-month Senores Pharmaceuticals share price target 2026 is Rs 1,500, implying approximately 20 percent upside from CMP Rs 1,270. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.
Long Term Senores Pharmaceuticals Share Price Target: FY27 to FY28
The long term Senores Pharmaceuticals share price target for FY27 to FY28 is Rs 1,850 in the bull case, requiring full earnings delivery, re-rating among peers in pharma export like Alembic Pharmaceuticals and Neuland Laboratories, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Senores Pharmaceuticals in 2026
Bull Case Senores Pharmaceuticals Share Price Target: Rs 1,850
The bull case Senores Pharmaceuticals share price target of Rs 1,850 materialises when FY27 earnings beat analyst estimates, Generic Pharmaceuticals Export tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 1,270.
Bear Case Senores Pharmaceuticals Share Price Target: Rs 1,000
The bear case Senores Pharmaceuticals share price target of Rs 1,000 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 532.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 1,850 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 1,500 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 1,000 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Senores Pharmaceuticals 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Senores Pharmaceuticals share price target of Rs 1,500, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 1,500 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Generic Pharmaceuticals Export Peers
Intensifying competition from peers in pharma export like Alembic Pharmaceuticals and Neuland Laboratories could compress Senores Pharmaceuticals’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 1,500 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.
How to Invest in Senores Pharmaceuticals
Check the Univest Screener for live data
Before considering any investment based on the Senores Pharmaceuticals share price target of Rs 1,500, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Generic Pharmaceuticals Export sector demand.
Open a Demat account with a SEBI registered stockbroker to trade Senores Pharmaceuticals (NSE: SENORES) with full regulatory protection. Study the competitive landscape among peers in pharma export like Alembic Pharmaceuticals and Neuland Laboratories before executing any position.
Plan your entry using the 52 week low of Rs 532 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 1,500 price objective. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Senores Pharmaceuticals’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Senores Pharmaceuticals Share Price Target 2026
What is the Senores Pharmaceuticals share price target for 2026?
Ans. The Senores Pharmaceuticals share price target 2026 is Rs 1,500, implying approximately 20 percent upside from CMP Rs 1,270. Bull case is Rs 1,850, bear case is Rs 1,000.
What was the Senores Pharmaceuticals share price target for 2025?
Ans. The 2025 price objective for Senores Pharmaceuticals was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 1,500, reflecting FY27 growth potential from CMP Rs 1,270.
Is Senores Pharmaceuticals a good investment at Rs 1,270?
Ans. At Rs 1,270, Senores Pharmaceuticals offers potential upside toward Rs 1,500 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Senores Pharmaceuticals share price target 2026?
Ans. Key risks to the Senores Pharmaceuticals share price target of Rs 1,500 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Generic Pharmaceuticals Export. Monitoring quarterly results is essential.
What is the 52 week high and low of Senores Pharmaceuticals?
Ans. The 52 week high of Senores Pharmaceuticals is Rs 1,360 and the 52 week low is Rs 532. At CMP Rs 1,270, the stock offers potential upside toward the Rs 1,500 price objective.
What are the main growth catalysts for Senores Pharmaceuticals in 2026?
Ans. Key catalysts include FY27 PAT recovery, Generic Pharmaceuticals Export tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Senores Pharmaceuticals compare to its peers?
Ans. Senores Pharmaceuticals operates in Generic Pharmaceuticals Export alongside peers in pharma export like Alembic Pharmaceuticals and Neuland Laboratories. At CMP Rs 1,270 with MCap Rs 5,844 crore, it is a potential re-rating candidate toward the Senores Pharmaceuticals share price target of Rs 1,500 on FY27 delivery.
What is the Senores Pharmaceuticals share price target for 2027?
Ans. The long-term Senores Pharmaceuticals share price target for FY27 to FY28 is Rs 1,850 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
